Aging Clinical Trial
Official title:
Evaluation of a Computational Model That Predicts the Effects of Quercetin on Metabolic Health Using Biological Age and Other Lipid-related Blood Metrics
Verified date | January 2023 |
Source | Thorne Research Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Quercetin is a natural flavonoid compound widely found in vegetables, fruits, and nuts. It has a long history of use as a dietary supplement. This study aims to assess results from a computational model suggesting that quercetin may offer novel benefits to metabolic health. Participants will take quercetin (as Quercetin Phytosome, a proprietary formulation with enhanced absorption properties) for 90 days while keeping lifestyle habits consistent throughout to estimate net effects of quercetin as much as possible. Blood samples will be collected at the beginning and end of the study to assess the effects of quercetin supplementation on metabolic health metrics such as LDL cholesterol, blood sugar, liver, kidney and immune function and calculated metabolic age. In addition, questionnaires will be completed to ensure compliance with study requirements and assess potential quercetin benefits in the participants' quality of life. This work will provide a proof-of-concept from a computational model of nutraceutical compounds and proposes a new application of quercetin in support of healthy human metabolism.
Status | Terminated |
Enrollment | 5 |
Est. completion date | September 2, 2022 |
Est. primary completion date | August 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: - Age: 20-70 years - Self-report that, within the past 6 months, a medical professional has informed them of, or a blood test result has shown high-healthy Low Density Lipoprotein (LDL) levels (preferred range, if known: 130-159 mg/dL) AND 2 or more of the following 4 (values are preferred, if known): - Low-healthy fasting High Density Lipoprotein (HDL < 50 mg/dL) - High-healthy fasting Triglycerides (TG 150-199 mg/dL) - High-healthy fasting Blood Sugar (Glucose 100-126 mg/dL) - Waist Circumference > 40 in for men or > 35 in for women (this may be self-measured) Also - Willing and able to travel to a Quest location for both blood draws - Willing and able to fast (except water) for 12 hours prior to each blood draw - Willing and able to comply with the study schedule (+/- 2 days) - Willing and able to complete online questionnaires - Willing and able to check email for study-related messages regularly (daily) and to use email as the primary means of communication for non-emergency study-related contact with the study team - Informed consent to participate in the study discussed and signed - Willing and able to avoid making changes to diet, sleep, stress, exercise, and other lifestyle factors that may influence the study metrics - Willing and able to avoid use of the following supplements during the study: - Quercetin, Berberine, Red Yeast Rice, Fish Oil, Bergamot Juice Extract, Pantethine, Vitamin D3 dosing over 5,000IU daily, Pterostilbene, Aged Garlic, Phytosterols, Niacin (crystalline/acid, not niacinamide), Meriva/curcumin/turmeric Exclusion Criteria: - Individuals who live in NY, NJ, RI, SD, ND, HI, or MD (due to lack of availability of WellnessFX or Quest services) - Individuals who are currently taking any lipid-lowering medications (including statins) or have taken them within the past 6 months. - Individuals who are currently taking or have taken any lipid-lowering supplements (including quercetin) consistently in the past 4 weeks. Excluded supplements are products that contain: o Berberine, Red Yeast Rice, Fish Oil, Bergamot Juice Extract, Pantethine, Vitamin D3 dosing over 5,000IU daily, Pterostilbene, Aged Garlic, Phytosterols, Niacin (crystalline/acid, not niacinamide), Meriva/curcumin/turmeric - Diagnosed with metabolic syndrome - Being treated for hypertension - Known allergy or sensitivity to any components of the trial's nutritional supplement - Myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, or stent within five years - Known clinical coronary heart disease symptoms - Known clinical angina - History of cerebrovascular accident - Creatinine > 2.5 mg/dL - Chronic liver disease with AST, ALT, or alkaline phosphatase over 1.5 times normal - Known cancer within two years - Clinical congestive heart failure (systolic or diastolic CHF) - Type 1 or type 2 diabetes mellitus - Habitual drinking (cutoff at PI discretion using the following guidelines: 8 or more drinks a week) or being a current smoker/vaping - Pregnant or nursing - Women of child-bearing age not using an approved contraceptive - Planned major surgery during the study (1 week before first blood draw and during the 90-day supplementation) |
Country | Name | City | State |
---|---|---|---|
United States | This is a remote study - participants will find a commercial lab location near them. | Summerville | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Thorne Research Inc. | Indena S.p.A |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Biological Age score from before (day 0) to after (day 90) supplementation | Quantitative changes before and after intervention in calculated metrics of biological age.
These metrics are calculated by applying the Klemera-Doubal algorithm to a proprietary set of clinical measures. (Scale for each metric: 0-120) (ref: https://academic.oup.com/biomedgerontology/article/74/Supplement_1/S52/5625183?login=true) |
90 days | |
Primary | Change in Apolipoprotein B from before (day 0) to after (day 90) supplementation | Quantitative changes before and after intervention in Apolipoprotein B test (Quest Diagnostics 91726) (Scale: mg/dL) | 90 days | |
Primary | Change in Lipoprotein Fractions from before (day 0) to after (day 90) supplementation | Quantitative changes before and after intervention in Lipoprotein Fractionation, Ion Mobility test (Quest Diagnostics 91604) (Scale: particle number) | 90 days | |
Primary | Quality of Life scale changes from before (day 0) to after (day 90) supplementation | Quantitative changes in The Quality of Life Scale (Scale: 1-100 as determined by ref: http://www.jstor.org/stable/4034400) | 90 days | |
Secondary | Lifestyle changes from before (day 0) to after (day 90) supplementation | Quantitative changes among any time points in metrics of lifestyle measured by questionnaire.
Questionnaire metrics and scales: Stress: 1-10 (little or none:1, extreme:10) Exercise: 1-10 (little or none:1, extreme:10) Diet: 1-10 (very unhealthy:1, very healthy:10) Sleep: 1-10 (very poor:1, excellent:10) |
90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |